Results 161 to 170 of about 39,316 (219)

A Survey Study of Patient‐Physician Communication and Treatment Decision‐Making Preference at Treatment Initiation and After Disease Stabilization in Newly Diagnosed Multiple Myeloma

eJHaem, Volume 7, Issue 2, April 2026.
ABSTRACT Introduction We present real‐world evidence of patient‐physician communication for patients with newly diagnosed multiple myeloma (NDMM) who have not received hematopoietic stem cell transplantation. Methods An observational survey study was conducted in Japan (September‒November 2024).
Hitoshi Hanamoto, Masaki Iino, Kyoko Joko, Kaho Kidera, Takahiro Yoshida, Kiyoshi Okazuka, Hirohiko Shibayama   +6 more
wiley   +1 more source

Scleredema Associated With IgG/κ Monoclonal Gammopathy of Clinical Significance Successfully Treated With Daratumumab Monotherapy: A Case Report

eJHaem, Volume 7, Issue 2, April 2026.
ABSTRACT Background Cutaneous monoclonal gammopathy of clinical significance (MGCS) is rare and may present with scleredema‐like fibrosing skin disease. Case A 59‐year‐old man developed progressive induration of the upper body. Laboratory studies revealed an IgG/κ monoclonal protein, and skin biopsy showed dermal thickening with mucin deposition.
Davide Marcolongo, Alessandra Bressan, Elisabetta Zanatta, Mauro S. A. Alaibac, Ilaria Gianesello, Gianni Binotto, Laura Pavan, Angelo Paolo Dei Tos, Livio Trentin, Fabrizio Vianello   +9 more
wiley   +1 more source

Genomic Proximity Mapping for Identification of Chromosomal Aberrations in Multiple Myeloma

American Journal of Hematology, Volume 101, Issue 4, Page 899-903, April 2026.
Richard K. Kandasamy, Joel‐Sean Hsu, Steve Eacker, Hayley Mangelson, Zachary D. Stephens, Angela Dispenzieri, Esteban Braggio, P. Leif Bergsagel, Rafael Fonseca, S. Vincent Rajkumar, Shaji K. Kumar, Linda B. Baughn, Wilson I. Gonsalves, Akhilesh Pandey   +13 more
wiley   +1 more source

CAR T Cell Expansion Masquerading as Plasmacytosis: Case Report of Significant Lymphocytosis After Cilta‐Cel in Multiple Myeloma

eJHaem, Volume 7, Issue 2, April 2026.
ABSTRACT We report a case of delayed hypersensitivity dermatitis and an unusual lymphocyte expansion peaking at 45,000 cells/µL by Day +14 after ciltacabtagene autoleucel, a BCMA‐targeted CAR T therapy for multiple myeloma (MM). This marked post‐infusion lymphocytosis was initially mistaken for plasmacytosis but was confirmed by flow cytometry to be ...
Jack Shapiro, Timothy Oh, Brian Vadasz, George de Castro, Alyss Wilkey, Kristy Wolniak, Fenlu Zhu, Jayesh Mehta, Seema Singhal, Adam Lin   +9 more
wiley   +1 more source

Treatment Discontinuation After Achieving MRD Negativity in Multiple Myeloma in the Pre‐BCMA Era: A Prospective, Single‐Centre Study

eJHaem, Volume 7, Issue 2, April 2026.
ABSTRACT Objectives Minimal/measurable residual disease (MRD) negativity in multiple myeloma (MM) is associated with favourable outcomes; nonetheless, evidence supporting treatment discontinuation remains limited. We evaluated the feasibility of discontinuing antimyeloma therapy in patients with MRD negativity.
Kota Sato, Kenshi Suzuki, Shotaro Sugita, Ukyo Kondo, Miyu Watanabe, Moe Yogo, Tomomi Takei, Mizuki Ogura, Yu Abe, Taku Kikuchi, Nobuhiro Tsukada, Tadao Ishida   +11 more
wiley   +1 more source

Durable Remission of Highly Refractory Multiple Myeloma and Therapy‐Related MDS/AML After Allogeneic Hematopoietic Cell Transplantation: Reconsidering Its Role in the CAR‐T Era

eJHaem, Volume 7, Issue 2, April 2026.
ABSTRACT Therapy‐related myelodysplastic syndrome and acute myeloid leukemia (MDS/AML) are increasingly recognized as late complications of multiple myeloma (MM) treatment and are associated with a dismal prognosis. We report on a patient with highly refractory MM who developed therapy‐related MDS/AML during the course of multiple lines of anti‐myeloma
Tomoko Kumamoto, Kyoko Yoshihara, Mami Samori, Saki Takahashi, Fuyuki Yamagata, Yoshiyuki Fujita, Nobuto Utsunomiya, Satoshi Yoshihara   +7 more
wiley   +1 more source

Adding Bortezomib and Bendamustine to High‐Dose Melphalan in Autologous Haematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma—A Single Centre Retrospective Study

eJHaem, Volume 7, Issue 2, April 2026.
ABSTRACT Introduction High‐dose melphalan (HDM) followed by autologous haematopoietic stem cell transplantation (ASCT) remains the standard of care for eligible patients with multiple myeloma (MM). Our objective was to evaluate the effectiveness and safety of adding bortezomib and bendamustine to melphalan (BBM) compared with HDM for relapsed MM, and ...
Thomas Silfverberg, Honar Cherif, Emma Smitt, Kristina Carlson   +3 more
wiley   +1 more source

Application and Challenges of Chimeric Antigen Receptor T Cell Therapy in Systemic Rheumatic Diseases and Autoimmune Disorders

MedComm, Volume 7, Issue 4, April 2026.
CAR‐T cell therapy in systemic rheumatic diseases and autoimmune disorders. (This figure was created using BioRender.com.) ABSTRACT Chimeric antigen receptor T (CAR‐T) cell therapy, originally developed for hematologic malignancies, has emerged as a transformative candidate for systemic rheumatic diseases and autoimmune disorders (AIDs).
Zhidan Fan, Li Zhang, Haiguo Yu
wiley   +1 more source

Oncolytic Therapy: Delivery System and New Therapeutic Strategies for Cancer

MedComm, Volume 7, Issue 4, April 2026.
This review summarizes recent advances in nanoparticle‐ and cell‐mediated OVs delivery strategies that improve biodistribution and tumor targeting while limiting immune clearance. It also examines combination approaches that enhance therapeutic efficacy through tumor microenvironment modulation or immune activation, thereby overcoming immunosuppression
Sikan Jin, Yi Zhang, Ziling Zhou, Yaqi Zhang, Ting Yu, Rui Xu, Lin Xu, Jidong Zhang, Longze Zhang, Shan Yang, Xianyao Wang   +10 more
wiley   +1 more source

The Histone‐Lysine N‐Methyltransferase (KMT2) Family in Health and Disease

MedComm, Volume 7, Issue 4, April 2026.
This graphical abstract clarifies KMT2 family dysregulation and disease associations: its member mutations cause epigenetic imbalance and abnormal cell development; Menin/WDR5 inhibitors and other targeted therapies block aberrant epigenetic transcriptional programs, and combined synergistic therapies boost therapeutic efficacy.
Qiu Wang, Zunjie Bo, Ya Zhang, Yun Chen, Zhiyu Wang, Shuangmei Tong, Ajing Xu, Jian Zhang, Yan Liu   +8 more
wiley   +1 more source